Experimental CAR-T therapy takes on lupus and scleroderma
NCT ID NCT07523282
First seen Apr 21, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This early-stage trial tests a new drug called HN2302, a type of CAR-T cell therapy made inside the body, for people with autoimmune diseases like lupus and scleroderma. The study will enroll 12 adults to check safety and see if it works. Researchers will monitor side effects and measure how well the therapy targets immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230036, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HN2302 (in vivo CAR-T cell therapy)
What this could lead to
If successful, this could point toward a new way to control autoimmune diseases like lupus and scleroderma without needing lifelong medication.
What could go wrong
This is a very early Phase 1 trial with only 12 people, so safety and effectiveness are unknown. The therapy may fail or cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.